Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Public ClinicalTrials.gov record NCT04121676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Study identification
- NCT ID
- NCT04121676
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2019 (Actual)
- Primary completion
- Feb 22, 2024 (Actual)
- Completion
- Nov 30, 2024 (Actual)
- Last update posted
- Jan 13, 2025
2019 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California Norris Comprehensive Cancer Center/ Hoag | Los Angeles | California | 90033 | — |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| University of Miami | Coral Gables | Florida | 33146 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Roswell Park Comprehensive Cancer Care | Buffalo | New York | 14203 | — |
| Columbia University | New York | New York | 10032 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| UPMC | Pittsburgh | Pennsylvania | 15232 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75230 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04121676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04121676 live on ClinicalTrials.gov.